APPL.BO · BSE
Aptus Pharma Limited
₹353.4
+1.99% (+₹6.9)
Prev. close
₹346.5
Volume
8,400
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Aptus Pharma Limited
Aptus Pharma Limited engages in the marketing and distribution of finished pharmaceutical formulations. The company operates through four divisions: Aptus Pharma, Pioneer division, which includes marketing of acute therapies including general anti-infectives, pain management, antacids, and gastrointestinal drugs; Aptus CD Care, Cardiac Diabetic division, which includes marketing of chronic therapies, including antihypertensive, anti-diabetic, and lipid-lowering; Aptus Wellcare offers wellness and nutraceutical products, over-the-counter (OTC) formulations, and personal care products; and Aptus Global, export division engages in exploring and developing opportunities in overseas markets, semi-regulated and emerging countries. It also offers anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, antidiabetic, lipid-lowering, and general wellness products. In additio, the company develops and markets skin care, face care, hair care, personal hygiene, wellness, and self-care over-the-counter products. Its products are available in balms, capsules, drops, gels, injections, lotions, ointments, powders, sachets, softgels, solutions, suspensions, syrups, tablets, and vials. It distributes the products through clearing and forwarding agents. Aptus Pharma Limited was incorporated in 2010 and is headquartered in Rajkot, India.
Details
Sector
Healthcare
Industry
Medical Distribution
CEO
Mr. Ghanshyam Vinubhai Pansuriya
Headquarters
Rajkot
Employees
91
Website
aptus-pharma.comExchange
View on BSE ↗Key stats
Market cap
₹606.08 Cr
P/E ratio (TTM)
113.6
EPS (TTM)
₹3.11
Beta (1Y · daily vs NIFTY 50)
-0.08
Shares float
36.90 L
EPS · quarter ended Mar 2026
₹1.68
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹13.90 Cr | ₹17.86 Cr | ₹24.56 Cr | ₹46.58 Cr | |
| EBITDA | ₹57.46 L | ₹1.49 Cr | ₹4.76 Cr | ₹7.58 Cr |
| ₹19.43 L | ₹79.81 L | ₹3.10 Cr | ₹4.62 Cr | |
| Diluted EPS | ₹0.11 | ₹0.47 | ₹1.81 | ₹3.11 |
Total expenses (as filed), Employee benefit expense, Other expenses have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹6.22 Cr | ₹10.03 Cr | ₹21.92 Cr | ₹43.53 Cr | |
| ₹2.21 Cr | ₹5.31 Cr | ₹10.36 Cr | ₹7.18 Cr | |
| Stockholders' equity | ₹96.84 L | ₹1.77 Cr | ₹6.97 Cr | ₹23.35 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹-18.10 L | ₹-2.17 Cr | ₹-1.84 Cr | ₹-5.60 Cr | |
| Investing cash flow | ₹-35.30 L | ₹-30.45 L | ₹-54.46 L | ₹-6.17 Cr |
| ₹81.01 L | ₹2.86 Cr | ₹6.68 Cr | ₹8.59 Cr | |
| Capital expenditure | ₹-35.30 L | ₹-32.97 L | ₹-62.16 L | ₹-2.19 Cr |
| End cash position | ₹53.66 L | ₹91.46 L | ₹5.21 Cr | ₹1.03 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Aptus Pharma Limited | ₹594.25 Cr | ₹353.55 | 111.1 | 25.45 | 19.8% | 0.31 | +89.7% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Aptus Pharma Limited Charts Next Growth Phase with Focus on Manufacturing, PAN-India Expansion and Global Markets
Q-Line Biotech Ltd. is launching an IPO of 6,253,200 equity shares to raise Rs. 214.48 crore, with a price band of Rs. 326-Rs. 343 per share. The company, which manufactures and markets diagnostic reagents and equipment, plans to use the proceeds for working capital and debt repayment. The IPO opens on May 21, 2026, and will list on NSE SME Emerge.
Aptus Pharma to raise Rs 45 crore; plans manufacturing push, global expansion
Aptus Pharma plans to raise Rs 45 crore through a preferential issue, pending shareholder approval on September 14, 2026. The funds will support a manufacturing push to meet 20% of product needs in-house and expand its sales network across India. The company also aims for global expansion into Africa, the Middle East, and Latin America.